Get the Stockscreener App
0.825
8.82%
-0.0798
Atossa Therapeutics Inc stock is traded at $0.825, with a volume of 1.18M.
It is down -8.82% in the last 24 hours and up +1.44% over the past month.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
See More
Previous Close:
$0.9048
Open:
$0.8817
24h Volume:
1.18M
Relative Volume:
1.25
Market Cap:
$106.57M
Revenue:
-
Net Income/Loss:
$-26.91M
P/E Ratio:
-3.75
EPS:
-0.22
Net Cash Flow:
$-19.57M
1W Performance:
+3.22%
1M Performance:
+1.44%
6M Performance:
-4.38%
1Y Performance:
-28.26%
1-Day Range:
$0.8202
$0.914
1-Week Range:
$0.77
$0.99
52-Week Range:
$0.5526
$1.29
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.825 | 116.87M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track - Stocktwits
Trade Recap: Will Atossa Therapeutics Inc stock gain from lower inflationJuly 2025 Chart Watch & Weekly Chart Analysis and Guides - moha.gov.vn
Atossa gains on rare pediatric disease status for Duchenne asset - MSN
Atossa Therapeutics, Inc. (ATOS) -6.4% in After-hours: Shares Slip Amid Routine Trading - Stocks Telegraph
Atossa Therapeutics (ATOS) Stock: Soars 8% as FDA Grants Rare Pediatric Disease Designation for (Z)-Endoxifen (ATOS) - parameter.io
Why Are Shares Of Atossa Therapeutics Up Today? - Benzinga
Atossa Therapeutics (ATOS) Surges on FDA Pediatric Designation - GuruFocus
Atossa gains on Rare Pediatric Disease status for Duchenne asset - Seeking Alpha
Atossa Therapeutics stock soars after FDA grants rare pediatric disease status - Investing.com UK
Atossa Therapeutics stock soars after FDA grants rare pediatric disease status By Investing.com - Investing.com Nigeria
Atossa Therapeutics (ATOS) Gains FDA Recognition for Duchenne Mu - GuruFocus
Atossa Therapeutics (NASDAQ: ATOS) gets FDA RPD tag; PRVs fetch $100–$160 million - Stock Titan
Adversity is less terrifying than hope: Atossa Therapeutics Inc (ATOS) - setenews.com
Atossa Therapeutics Announces Issuance of U.S. Patent Covering E - GuruFocus
ATOS Receives New Patent for Endoxifen Formulations - GuruFocus
Atossa Therapeutics receives US patent for endoxifen formulations - Investing.com
Atossa Therapeutics (Nasdaq: ATOS) lands U.S. patent with 100 (Z)-endoxifen claims - Stock Titan
Ascendiant Capital raises Atossa Genetics stock price target to $8 from $7.75 - Investing.com Canada
Ascendiant Capital Markets Forecasts Strong Price Appreciation for Atossa Genetics (NASDAQ:ATOS) Stock - MarketBeat
Ascendiant Capital Maintains Atossa Therapeutics (ATOS) Buy Recommendation - Nasdaq
Ascendiant Capital Raises Price Target for Atossa Therapeutics (ATOS) | ATOS Stock News - GuruFocus
CapEx per share of Atossa Therapeutics, Inc. – BER:YAG2 - TradingView
Analysts Set Atossa Genetics Inc. (NASDAQ:ATOS) Price Target at $6.25 - Defense World
Contrasting Vaso (OTCMKTS:VASO) and Atossa Genetics (NASDAQ:ATOS) - Defense World
Atossa Genetics stock holds Buy rating at H.C. Wainwright on FDA feedback By Investing.com - Investing.com South Africa
Atossa Genetics stock holds Buy rating at H.C. Wainwright on FDA feedback - Investing.com Canada
Is Atossa Therapeutics Inc. stock undervalued vs historical averagesIPO Watch & Weekly Market Pulse Alerts - Newser
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum - Finviz
Will Atossa Therapeutics Inc. stock outperform tech sector in 2025July 2025 Recap & Safe Capital Investment Plans - Newser
Is Atossa Therapeutics Inc. (YAG2) stock a buy before new product rolloutQuarterly Portfolio Report & Fast Momentum Entry Tips - Newser
Atossa completes FDA meeting on regulatory strategies - MSN
Atossa Completes FDA Meeting on Regulatory Strategies - TipRanks
Atossa Therapeutics Completes FDA Meeting on (Z)-Endoxifen Strategy - TradingView
Atossa Genetics Inc. (NASDAQ:ATOS) Given Average Rating of "Hold" by Analysts - MarketBeat
Is Atossa Therapeutics Inc. (YAG2) stock considered safe havenJuly 2025 Intraday Action & AI Driven Stock Movement Reports - Newser
Is Atossa Therapeutics Inc. (YAG2) stock good for long term investingWeekly Investment Summary & Low Risk Entry Point Guides - Newser
Will Atossa Therapeutics Inc. stock beat EPS estimates2025 Key Highlights & High Return Stock Watch Alerts - Newser
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma - Lelezard
How Atossa Therapeutics Inc. (YAG2) stock performs in easing cyclesWeekly Trend Summary & Risk Controlled Stock Pick Alerts - Newser
Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Invest In Growth? - Sahm
Insilico Medicine and Atossa Therapeutics publish AI-driven study in Nature's Scientific Reports identifying (Z)-endoxifen as a potential therapeutic candidate for glioblastoma - EurekAlert!
S P Trends: How buybacks impact ARMOUR Residential REIT Inc stock valuePrice Action & Daily Profit Maximizing Trade Tips - BỘ NỘI VỤ
Atossa Therapeutics (ATOS) Advances Glioblastoma Research with A - GuruFocus
Can Atossa Therapeutics Inc. (YAG2) stock surprise with quarterly results2025 Momentum Check & Fast Gain Stock Tips - Newser
Published on: 2025-12-02 04:01:13 - Newser
Will Atossa Therapeutics Inc. (YAG2) stock hit Wall Street targetsOptions Play & Precise Trade Entry Recommendations - Newser
Atossa (Nasdaq: ATOS) and Insilico map 1,400 GBM genes to (Z)-endoxifen in AI study - Stock Titan
Atossa Therapeutics (ATOS) Stock Analysis Report | Financials & Insights - Benzinga
Will Atossa Therapeutics Inc. stock outperform international peersJuly 2025 Levels & Fast Moving Market Watchlists - BỘ NỘI VỤ
Is Atossa Therapeutics Inc (ATOS) positioned for future growth? - Setenews
Is Atossa Therapeutics Inc. stock a buy before product launches2025 Major Catalysts & Verified Momentum Watchlists - BỘ NỘI VỤ
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atossa Therapeutics Inc Stock (ATOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):